SARS-CoV-2 Infection Presenting as Acute Chest Syndrome in a Child With Hemoglobin SD-Los Angeles Disease: A Case Report and Review of Literature
- 26 September 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (2) , 82-87
Abstract
Hemoglobin D-Los Angeles is a variant of hemoglobin that can polymerize in the deoxygenated state. When co-inherited with Hemoglobin S (HbSD-Los Angeles disease) a severe sickling syndrome similar to HbSS can result. Corona virus infectious disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome-corona virus-2. It has been associated with acute chest syndrome (ACS) in individuals with sickle cell disease (SCD), but this complication has not previously been reported in patients with HbSD-Los Angeles. Dexamethasone has been shown to improve outcomes in non-SCD patients with severe acute respiratory syndrome-corona virus-2 pneumonia or acute respiratory distress syndrome; however, its use in SCD patients with ACS is controversial due to a reported increased risk of complications including vaso-occlusive painful episodes. Herein, we reported a patient with HbSD-Los Angeles and COVID-19-associated ACS whom we treated with dexamethasone without transfusion. The patient experienced a rapid recovery without sequelae from steroid use. To further evaluate the use of steroids, we conducted a literature review focusing on the management of pediatric SCD patients with COVID-19-associated ACS. We identified a total of 39 pediatric patients with SCD and COVID-19, of whom 21 (54%) had ACS. Packed red blood cell transfusion (n=11), exchange transfusion (n=4), or a combination of exchange transfusion and packed red blood cell transfusion (n=4) were the most frequently reported treatment, with hydroxychloroquine (n=5), remdesivir (n=1), and tocilizumab (n=1) also being reported. Three patients were treated with dexamethasone. All patients recovered and no adverse outcomes from steroid use were reported. Even though transfusion is considered the standard of care for children with ACS and steroids are not routinely recommended, our experience suggested that COVID-19-associated ACS may be an important exception, especially for patients who refuse transfusion or are in resource-poor nations where blood transfusions may not be readily available. Further studies are warranted to confirm these observations.Keywords
All Related Versions
This publication has 49 references indexed in Scilit:
- Variable Phenotypic Presentation of Two Siblings with Hemoglobin SD DiseaseIndian Journal of Pediatrics, 2020
- Clinical, hematological and genetic data of a cohort of children with hemoglobin SDRevista Brasileira de Ginecologia e Obstetrícia, 2016
- How I treat acute chest syndrome in children with sickle cell diseaseBlood, 2011
- Corticosteroids for acute chest syndrome in children with sickle cell disease: Variation in use and association with length of stay and readmissionAmerican Journal of Hematology, 2009
- Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell DiseaseNew England Journal of Medicine, 2000
- Beneficial Effect of Intravenous Dexamethasone in Children With Mild to Moderately Severe Acute Chest Syndrome Complicating Sickle Cell DiseaseBlood, 1998
- The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell DiseaseBlood, 1994
- Hb D Los Angeles (D-Punjab) and Hb Presbyterian: analysis of the defect at the DNA levelHuman Genetics, 1990
- Life-Twieatening Complications in a Child with Hemoglobin Sd-Los Angeles DiseaseHemoglobin, 1984
- Clinical Manifestations of Inherited Abnormal HemoglobinsBlood, 1955